COSCIENS Biopharma Inc.CSCI.TO

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · cosciensbio.com

COSCIENS Biopharma Inc. (formerly Aeterna Zentaris) is a Canadian life science company that develops and commercializes natural, plant-based active ingredients derived from oats and pharmaceutical products through its subsidiary Ceapro. The company serves the cosmeceutical, nutraceutical, and pharmaceutical markets and also markets Macrilen (macimorelin), an orally active growth hormone stimulator. COSCIENS is headquartered in Edmonton, Alberta.

Key ratios

FCF / Sales

-122.4%TTM

2025 -122.4%2024 -164.1%2023 -46.3%

Net margin

-138.1%TTM

2025 -138.1%2024 -159.7%2023 -48.8%

ROA

-23.1%TTM

2025 -23.1%2024 -21.1%2023 -7.3%

ROE

-121.8%TTM

2025 -121.8%2024 -89.5%2023 -12.3%

Recent news

COSCIENS Completes Second Tranche of Convertible Debenture Offering 2026-09-16 · GlobeNewswire Canadian Investment Regulatory Organization Trade Resumption - CSCI 2026-09-11 · CNW COSCIENS Acquires Nualtis Corp. 2026-09-10 · GlobeNewswire Canadian Investment Regulatory Organization Trading Halt - CSCI 2026-09-10 · CNW COSCIENS Biopharma Inc. Reports Q2 2026 Results 2026-08-11 · GlobeNewswire COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment 2026-06-23 · GlobeNewswire COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO 2026-06-18 · BioSpace

Track CSCI.TO in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer